IP Library Patent Application 18200148
Patent Application
App. No. 18/200,148

Methods for the Prevention and Treatment of Hearing Loss

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/200,148
Abstract

In one aspect, use of Afatinib as an active agent to treat a hearing loss and to prevent a hearing loss, and methods of treating and/or preventing hearing loss or disorders using the compositions are disclosed. In particular, a method for treating sensorineural hearing loss, including the steps of delivering to a patient in need thereof a composition comprising a therapeutically effective amount of Afatinib. or pharmaceutically acceptable salt thereof is provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims (13)

1 . A method of protecting ear cells from death caused by noise exposure comprising: administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is Afatinib.

2 . (canceled)

3 . A method to prevent hearing loss from an ototoxic event comprising: administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is Afatinib, wherein the ototoxic event is caused by a chemotherapeutic agent.

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . A kit comprising: an active agent, wherein the active agent is Afatinib, or a pharmaceutically acceptable salt thereof; and one or more of:

(A) an at least one chemotherapeutic agent;

(B) an at least one antibiotic; and

(C) instructions for preventing a hearing impairment.

9 . (canceled)

10 . The kit of claim 8 , wherein the at least one chemotherapeutic agent is cisplatin.

Assignments (6)
MERGER AND CHANGE OF NAME Recorded Oct 10, 2024
From: TING THERAPEUTICS LLC; TING THERAPEUTICS, INC.
To: TING THERAPEUTICS, INC
Reel/Frame 069143/0879 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2024
From: DIGUISEPPI, JOSEPH A.
To: TING THERAPEUTICS LLC
Reel/Frame 068270/0612 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2024
From: ZUO, JIAN
To: TING THERAPEUTICS LLC
Reel/Frame 068270/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2024
From: CREIGHTON UNIVERSITY
To: TING THERAPEUTICS LLC
Reel/Frame 068272/0190 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2024
From: CREIGHTON UNIVERSITY
To: TING THERAPEUTICS LLC
Reel/Frame 068252/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2024
From: ZUO, JIAN
To: TING THERAPEUTICS LLC
Reel/Frame 068254/0274 →